Lantern Pharma Inc expected to post a loss of 43 cents a share - Earnings Preview

Lantern Pharma

07/08/2023 21:57

* Lantern Pharma Inc  LTRN.OQ   LTRN.O  is expected to show
no
change in quarterly revenue when it reports  results on August
9. 
    * 
    * ​Refinitiv's mean analyst estimate for Lantern Pharma Inc
is for
a loss of 43 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lantern
Pharma
Inc is $15​, above​ its last closing price of $4.84. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023              -0.48      -0.36     Beat    25
 Dec. 31 2023              -0.47      -0.31     Beat    34
 Sep. 30 2022  -0.42       -0.48      -0.21     Beat    56.3​
 Jun. 30 2022  -0.52       -0.52      -0.41     Beat    21.2
 ​​Mar.        -0.29       -0.29      -0.38     Missed  -31
 31 2022                                                
 Dec. 31 2021  -0.43       -0.40      -0.32     Beat    20.7​
 Sep. 30 2021  -0.25       -0.27      -0.36     Missed  -35
 Jun. 30 2021  -0.26       -0.26      -0.21     Beat    19.2
 This summary was machine generated August 7 at 20:57 GMT.  All
figures in US dollars  unless otherwise stated